Core Viewpoint - The company, Heptagon Pharmaceuticals-B (02142), anticipates significant profit growth for the fiscal year ending December 31, 2025, projecting a profit between approximately $88 million (around HKD 685 million) and $95 million (around HKD 739 million), compared to a profit of about $2.7 million for the fiscal year ending December 31, 2024 [1] Group 1: Profit Forecast - The expected adjusted profit for the company ranges from $91 million (approximately HKD 708 million) to $98 million (approximately HKD 763 million) [1] - The profit increase is primarily attributed to the continuous growth of the company's recurring revenue [1] Group 2: Revenue Drivers - The growth in recurring revenue is driven by ongoing research collaborations with partners such as AstraZeneca and Bristol-Myers Squibb [1] - The global partnership network is expanding, leading to revenue from licensing and collaborations, including partnerships with Otsuka Pharmaceutical and Windward Bio [1] - Rapid growth in the business of Nona Bio, including revenue from technology licensing and platform-based services, as well as milestone payments from existing collaborations, such as research and technology licensing with Pfizer [1]
和铂医药-B盈喜后高开逾3% 预期年度溢利至多约9500万美元 公司经常性收入持续增长